Patients receiving sitagliptin with metformin and insulin had significant improvements in A1C, FPG and 2-hour PPG compared to patients receiving placebo with metformin and insulin (Table 13)
If you are still experiencing side effects at week four, extend the starting dose period by two to four additional weeks until symptoms resolve
The participant will have 27 visits with the A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week Intervention 1 Intervention 2 Not provided Anticipated Start Date Not provided Actual Start Date 2018-11-29 Anticipated Date of Last Follow-up 2025-03-10 Estimated Primary Completion Date Not provided Estimated Completion Date Not provided Actual Primary Completion Date 2020-06-26 Actual Completion Date 2020-06-26 Age Cohort Genders Accepts pregnant individuals Unspecified Accepts lactating individuals Unspecified Accepts healthy individuals No Inclusion Criteria: * Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent * Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening * Current daily basal insulin treatment greater than or equal to 0.2 U/kg/day * Body mass index between 18.5 and 29.0 kg/m\^2 (both inclusive) * HbA1c less than or equal to 9.0% Exclusion Criteria: * History or presence of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions
Side effect management In some cases, patients tolerate tirzepatide better or experience fewer gastrointestinal symptoms once their body adjusts
The difference with GLP-1, which degrades in less than one minute in the blood, is that Exendin-4 retains its activity for more than two hours
Personalized Protocol Your physician prescribes a titration schedule starting low and increasing dose every 4 weeks alongside nutrition and behavior support
